GALT Projected Dividend Yield
Galectin Therapeutics Inc ( NASDAQ : GALT )Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Co.'s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. Co.'s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. 20 YEAR PERFORMANCE RESULTS |
|
GALT Dividend History Detail GALT Dividend News GALT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |
